Medical devices, healthcare technology and the business of care
510(k) clearance · K262861

PureLift Pro Max

Xtreem Pulse, LLC · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONK262861

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for PureLift Pro Max, a transcutaneous electrical stimulator for aesthetic purposes, on September 11, 2026, under 510(k) number K262861. The applicant is Xtreem Pulse, LLC, and the application was received August 13, 2026. The product code is NFO, regulation number 882.5890, with neurology as the regulation medical specialty and review panel. SESE indicates clearance of this 510(k), not premarket approval of the device.

The available decision document describes a comparison involving a 2.8 mA (10 kΩ) parameter, judged different but technologically equivalent, with the stated conclusion that the difference does not raise a different question of safety or effectiveness. The document also references a predicate described as an FDA-cleared NFO cosmetic electrical stimulation device and a regulation name for a transcutaneous electrical nerve stimulator for pain relief. The source does not identify the predicate's 510(k) number, the specific changed component, or the full indications cleared for PureLift Pro Max; those details remain unknown here.

No clinical performance data, adverse event information or labeling text is present in the public information, so no efficacy or safety conclusions are drawn.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Sep 11, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262861
Regulatory pathway
510(k) premarket notification
Product code
NFO
Decision code
SESE
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, Transcutaneous Electrical, Aesthetic Purposes.

Product code
NFO
FDA device class
2

FDA decision timeline

  1. K262861 received

    Application receipt date recorded by FDA.

  2. K262861 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code NFO

Product / regulatory recordCompanyPathwayDecision dateSource
Foreo, Inc.510(k) clearanceOct 26, 2026FDA
Foreo, Inc.510(k) clearanceOct 22, 2026FDA
Guangdong Newdermo Biotech Co., Ltd.510(k) clearanceSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Xtreem Pulse, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
New York, NY

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records